Phenytoin (All indications)

Microcephaly / Small head circumference for gestational age

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9216
R31979
Pennell (Phenytoin), 2012 Microcephaly at birth (head circumference < 3 percentile) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 0.98 [0.26;3.69] C 4/48   6/71 10 48
ref
S9202
R31927
Holmes (Phenytoin) (Controls unexposed, disease free), 2001 Microcephaly at birth (Head circumference more than 2 SD below the mean value for the same race, sex and gestational age) during pregnancy (anytime or not specified) retrospective cohort unexposed, disease free excluded Adjustment: No 0.73 [0.09;5.88] C
excluded (control group)
1/87   8/508 9 87
ref
S9203
R31936
Holmes (Phenytoin) (Controls unexposed, sick), 2001 Microcephaly at birth (Head circumference more than 2 SD below the mean value for the same race, sex and gestational age) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.55 [0.05;6.14] C 1/87   2/96 3 87
ref
S9254
R32094
Battino (Phenytoin), 1999 Small head circumferences (at birth < 10th percentile) throughout pregnancy prospective cohort unexposed, sick Adjustment: No 0.57 [0.13;2.45] C 6/100   3/30 9 100
ref
S9255
R32095
Díaz-Romero (Phenytoin), 1999 Head circumference <2 SD at birth (measured by a physician and correlated with sex and with gestational age) during pregnancy (anytime or not specified) cohort unexposed, sick Adjustment: No 0.37 [0.01;20.14] C 0/21   0/8 0 21
ref
S9274
R32159
Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997 Microcephaly at unknown age (head circumference ≤ 2 SD from the mean of children of the same age and sex) at least 1st trimester prospective cohort unexposed, sick Adjustment: No Controls: epilepsy indication 1.39 [0.06;31.88] C 2/33   0/9 2 33
ref
S9233
R32039
Kelly (Phenytoin), 1984 Microcephaly at unknown age (head circumference < 5th centile) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 0.50 [0.03;8.42] C 1/41   1/21 2 41
ref
Total 6 studies 0.72 [0.32;1.63] 26 330
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Pennell (Phenytoin), 2012Pennell, 2012 1 0.98[0.26; 3.69]104838%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Holmes (Phenytoin) (Controls unexposed, sick), 2001Holmes, 2001 2 0.55[0.05; 6.14]38711%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Battino (Phenytoin), 1999Battino, 1999 3 0.57[0.13; 2.45]910032%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: moderateROB mesure: moderateROB reporting: moderate Díaz-Romero (Phenytoin), 1999Díaz-Romero, 1999 4 0.37[0.01; 20.14]0214%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997Nulman, 1997 5 1.39[0.06; 31.88]2337%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Kelly (Phenytoin), 1984Kelly, 1984 6 0.50[0.03; 8.42]2418%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (6 studies) I2 = 0% 0.72[0.32; 1.63]263300.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Phenytoin; 2: Phenytoin) (Controls unexposed, sick; 3: Phenytoin; 4: Phenytoin; 5: Phenytoin) (Controls unexposed, sick) (Mixed indications; 6: Phenytoin;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.72[0.32; 1.63]263300%NAPennell (Phenytoin), 2012 Holmes (Phenytoin) (Controls unexposed, sick), 2001 Battino (Phenytoin), 1999 Díaz-Romero (Phenytoin), 1999 Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997 Kelly (Phenytoin), 1984 6 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.60[0.21; 1.68]162820%NAHolmes (Phenytoin) (Controls unexposed, sick), 2001 Battino (Phenytoin), 1999 Díaz-Romero (Phenytoin), 1999 Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997 Kelly (Phenytoin), 1984 5 exposed to other treatment, sickexposed to other treatment, sick 0.98[0.26; 3.69]1048 -NAPennell (Phenytoin), 2012 1 Tags Adjustment   - No  - No 0.72[0.32; 1.63]263300%NAPennell (Phenytoin), 2012 Holmes (Phenytoin) (Controls unexposed, sick), 2001 Battino (Phenytoin), 1999 Díaz-Romero (Phenytoin), 1999 Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997 Kelly (Phenytoin), 1984 6 Controls   - epilepsy indication  - epilepsy indication 1.39[0.06; 31.88]233 -NANulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997 1 All studiesAll studies 0.72[0.32; 1.63]263300%NAPennell (Phenytoin), 2012 Holmes (Phenytoin) (Controls unexposed, sick), 2001 Battino (Phenytoin), 1999 Díaz-Romero (Phenytoin), 1999 Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997 Kelly (Phenytoin), 1984 60.15.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.84.52.4540.000Pennell (Phenytoin), 2012Holmes (Phenytoin) (Controls unexposed, sick), 2001Battino (Phenytoin), 1999Díaz-Romero (Phenytoin), 1999Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997Kelly (Phenytoin), 1984

Asymetry test p-value = 0.5353 (by Egger's regression)

slope=-0.0536 (0.4341); intercept=-0.2890 (0.4266); t=0.6774; p=0.5353

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 9202

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.73[0.09; 5.88]987 -NAHolmes (Phenytoin) (Controls unexposed, disease free), 2001 1 unexposed, sick controlsunexposed, sick controls 0.60[0.21; 1.68]162820%NAHolmes (Phenytoin) (Controls unexposed, sick), 2001 Battino (Phenytoin), 1999 Díaz-Romero (Phenytoin), 1999 Nulman (Phenytoin) (Controls unexposed, sick) (Mixed indications), 1997 Kelly (Phenytoin), 1984 5 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.98[0.26; 3.69]1048 -NAPennell (Phenytoin), 2012 10.510.01.0